Diffuse large B-cell lymphoma: open trials in Japan

8 open trials have a site in Japan. Registry data; only the trial team decides who can take part.

NCT07226843
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Trial Treatment · Phase 1 · Eli Lilly and Company
National Cancer Center Hospital East, Chiba · Okayama University Hospital, Okayama · Cancer Institute Hospital of JFCR, Tokyo
Registry updated 2026-11-04
NCT05139017
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Trial Treatment · Phase 2/3 · Merck Sharp & Dohme LLC
Tokyo Metropolitan Komagome Hospital ( Site 3200), Bunkyo · University of Yamanashi Hospital ( Site 3201), Chūō · National Hospital Organization Kyushu Cancer Center ( Site 3204), Fukuoka · Fukushima Medical University Hospital ( Site 3207), Fukushima · Kansai Medical University Hospital ( Site 3203), Hirakata · Tokai University Hospital ( Site 3212), Isehara · University Hospital,Kyoto Prefectural University of Medicine ( Site 3209), Kyoto · The Jikei University Hospital ( Site 3208), Minato · University of Miyazaki Hospital ( Site 3211), Miyazaki · Osaka Metropolitan University Hospital ( Site 3205), Osaka · Hokkaido University Hospital ( Site 3202), Sapporo · Mie University Hospital ( Site 3210), Tsu · Yamagata University Hospital ( Site 3206), Yamagata
Registry updated 2026-11-03
NCT06890884
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Trial Treatment · Phase 2 · Merck Sharp & Dohme LLC
Nippon Medical School Hospital ( Site 1001), Bunkyo · National Cancer Center Hospital ( Site 1009), Chūō · Kansai Medical University Hospital ( Site 1006), Hirakata · Shimane University Hospital ( Site 1002), Izumo · Nagasaki University Hospital ( Site 1008), Nagasaki · Aichi Cancer Center ( Site 1007), Nagoya · Hokkaido University Hospital ( Site 1004), Sapporo · National Hospital Organization Sendai Medical Center ( Site 1005), Sendai · Fujita Health University Hospital ( Site 1003), Toyoake
Registry updated 2026-11-03
NCT06717347
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Juntendo University Hospital ( Site 3307), Bunkyo · Tokyo Metropolitan Komagome Hospital ( Site 3323), Bunkyo · Chiba Cancer Center ( Site 3314), Chiba · University of Yamanashi Hospital ( Site 3320), Chūō · Kyushu University Hospital ( Site 3313), Fukuoka · Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital ( Site 3322), Hiroshima · Saitama Medical University Hospital ( Site 3305), Iruma-gun · Tokai University Hospital ( Site 3302), Isehara · Kanazawa University Hospital ( Site 3308), Kanazawa · National Cancer Center Hospital East ( Site 3303), Kashiwa · Kobe City Medical Center General Hospital ( Site 3318), Kobe · University Hospital,Kyoto Prefectural University of Medicine ( Site 3315), Kyoto · National Hospital Organization Shikoku Cancer Center ( Site 3321), Matsuyama · University of Miyazaki Hospital ( Site 3319), Miyazaki · Nagoya University Hospital ( Site 3309), Nagoya · Okayama University Hospital ( Site 3311), Okayama · Osaka Metropolitan University Hospital ( Site 3317), Osaka · Kindai University Hospital ( Site 3310), Sakai · Tohoku University Hospital ( Site 3301), Sendai · Yamagata University Hospital ( Site 3312), Yamagata
Registry updated 2026-10-21
NCT03460977
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Trial Treatment · Phase 1 · Pfizer
National Cancer Center Hospital East, Kashiwa
Registry updated 2026-10-15
NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Trial Treatment · Phase 1/2 · BeOne Medicines
Chiba Cancer Center, Chiba · National Cancer Center Hospital East, Kashiwa · Cancer Institute Hospital of JFCR, Kōtoku · Aichi Cancer Center Hospital Clinical Oncology, Nagoya · Yokohama Municipal Citizens Hospital, Yokohama
Registry updated 2026-10-05
NCT04094311
Study of Out of Specification for Tisagenlecleucel
Trial Treatment · Phase 3 · Novartis Pharmaceuticals
Aomori · Bunkyo Ku · Chiba · Chuo Ku · Fuchū · Fukuoka · Gifu · Hamamatsu · Hiroshima · Ishikawa · Izumi · Izumisano · Izumo · Kita-gun · Kobe · Kumamoto · Kurashiki · Kyoto · Matsumoto · Minato Ku · Nagasaki · Nagoya · Niigata · Nishinomiya · Okayama · Osaka · Saitama · Sakai · Sapporo · Sendai · Setagaya-ku · Shinjuku Ku · Suita · Tōon · Tsu · Tsukuba · Wakayama · Yokohama · Yufu
Registry updated 2026-09-15
NCT07288879
DALY II Japan/MB-CART2019.1 for DLBCL
Trial Treatment · Phase 2 · Miltenyi Biomedicine GmbH
Tokyo Metropolitan Komagome Hospital, Tokyo · National Cancer Center Hospital, Tokyo · Toranomon Hospital, Tokyo · Keio University Hospital, Tokyo · Juntendo University Hospital, Tokyo
Registry updated 2026-01-08

All Diffuse large B-cell lymphoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error